PDF herunterladen
Thromb Haemost 2021; 121(10): 1289-1298
DOI: 10.1055/s-0041-1725009
Coagulation and Fibrinolysis

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

Masahiro Takeyama 
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Shoko Furukawa
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
2   The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan
,
Koji Yada
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
3   The Course of Hemophilia Education, Nara Medical University, Kashihara, Nara, Japan
,
Kenichi Ogiwara
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Naruto Shimonishi
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Yuto Nakajima
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Kuniyoshi Mizumachi
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Mariko Noguchi-Sasaki 
4   Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan
,
Midori Shima
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Keiji Nogami
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
› Institutsangaben Funding This work was partly supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) to K.N. (18K07885).
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Introduction Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A (PwAHAs) at diagnosis. However, coagulant effects of emicizumab in PwAHAs during the clinical course remain unclear.

Aim To assess ex vivo coagulant effects of emicizumab in PwAHAs during the clinical course.

Methods/Results Blood samples were obtained from 14 PwAHAs on (median) days 0 and 6 during a severe-bleeding phase, and days 27 and 59 during a reduced-bleeding phase with elevated endogenous factor VIII (FVIII) and decreased inhibitor titers. If administered a single dose of 3 or 6 mg/kg, or two doses at 6 mg/kg followed by 3 mg/kg, estimated plasma emicizumab concentrations (10/5/2.5, 20/10/5, and 30/15/7.5 µg/mL on days 0–7/30/60, respectively) could be used to represent potential changes, based on the half-life (T 1/2: ∼30 days). Emicizumab concentrations that covered maximum plasma concentrations of each dosage were used for spiking on day 0. Ex vivo addition of estimated emicizumab to PwAHA's plasma containing endogenous FVIII and/or inhibitor, without and with recombinant (r)FVIIa administration during immunosuppressive therapy, increased the calculated Ad|min1| values, assessed by clot waveform analysis, and their coagulant potentials were below normal levels. Rotational thromboelastometry revealed that ex vivo emicizumab addition resulted in the further improvement of coagulant potentials in whole bloods when combined with rFVIIa administration.

Conclusion Based on ex vivo and in vitro data, emicizumab has the potential to be effective in clinical situations for PwAHAs.

Keywords

bispecific - acquired hemophilia A - autoantibodies - pharmacokinetic - coagulation

Author Contributions

M.T. designed the research, provided clinical support, performed experiments, analyzed, and interpreted the data, made the figures, and wrote the paper. S.F., K.Y., K.O., N.S., Y.N., and K.M. provided clinical support. M.N.-S. prepared emicizumab and interpreted the data. M.S. supervised this study. K.N. designed the research, provided clinical support, interpreted the data, wrote the paper, edited the manuscript, and approved the final version to be published.




Publikationsverlauf

Eingereicht: 03. November 2020

Angenommen: 06. Januar 2021

Artikel online veröffentlicht:
28. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost 2013; 110 (06) 1114-1120
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125 (07) 1091-1097
    CrossrefPubMedGoogle Scholar
  • 3 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 2014; 40 (07) 803-811
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Collins PW, Hirsch S, Baglin TP. et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (05) 1870-1877
    CrossrefPubMedGoogle Scholar
  • 5 Knoebl P, Marco P, Baudo F. et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (04) 622-631
    CrossrefPubMedGoogle Scholar
  • 6 Baudo F, Collins P, Huth-Kühne A. et al; EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120 (01) 39-46
    CrossrefPubMedGoogle Scholar
  • 7 Kitazawa T, Igawa T, Sampei Z. et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
    CrossrefPubMedGoogle Scholar
  • 8 Sampei Z, Igawa T, Soeda T. et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8 (02) e57479
    CrossrefPubMedGoogle Scholar
  • 9 Shima M, Hanabusa H, Taki M. et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053
    CrossrefPubMedGoogle Scholar
  • 10 Shima M, Hanabusa H, Taki M. et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017; 1 (22) 1891-1899
    CrossrefPubMedGoogle Scholar
  • 11 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 12 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedGoogle Scholar
  • 13 Muto A, Yoshihashi K, Takeda M. et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014; 12: 206-213
    CrossrefPubMedGoogle Scholar
  • 14 Muto A, Yoshihashi K, Takeda M. et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124 (20) 3165-3171
    CrossrefPubMedGoogle Scholar
  • 15 Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46 (02) 121-123
    CrossrefPubMedGoogle Scholar
  • 16 Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 2019; 3 (03) 420-423
    CrossrefPubMedGoogle Scholar
  • 17 Al-Banaa K, Alhillan A, Hawa F. et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 2019; 20: 1046-1048
    CrossrefPubMedGoogle Scholar
  • 18 Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner KV, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137 (03) 410-419
    CrossrefPubMedGoogle Scholar
  • 19 Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost 2020; 18 (04) 825-833
    CrossrefPubMedGoogle Scholar
  • 20 Nogami K, Matsumoto T, Tabuchi Y. et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost 2018; 16 (06) 1078-1088
    CrossrefPubMedGoogle Scholar
  • 21 Kasper CK, Aledort L, Aronson D. et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (02) 612
    PubMedGoogle Scholar
  • 22 Matsumoto T, Nogami K, Ogiwara K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost 2012; 107 (02) 288-301
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 23 Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haematol 2020; 190 (05) 727-735
    CrossrefPubMedGoogle Scholar
  • 24 Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol 2016; 174 (04) 503-514
    CrossrefPubMedGoogle Scholar
  • 25 Yada K, Nogami K, Ogiwara K. et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol 2019; 110 (04) 419-430
    CrossrefPubMedGoogle Scholar
  • 26 Uchida N, Sambe T, Yoneyama K. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
    CrossrefPubMedGoogle Scholar
  • 27 Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 2019; 133 (05) 399-406
    CrossrefPubMedGoogle Scholar
  • 28 Majoor CJ, Sneeboer MM, de Kievit A. et al. The influence of corticosteroids on hemostasis in healthy subjects. J Thromb Haemost 2016; 14 (04) 716-723
    CrossrefPubMedGoogle Scholar
  • 29 Nogami K, Shima M, Giddings JC. et al. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. Blood 2001; 97 (03) 669-677
    CrossrefPubMedGoogle Scholar
  • 30 Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost 2019; 17 (08) 1269-1272
    CrossrefPubMedGoogle Scholar
  • 31 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
    CrossrefPubMedGoogle Scholar